EL7.AI
StocksMediumUpdated•Originally published 19 March 2026•Updated 19 March 2026•
1 min read

FiscalNote Holdings Reports Narrower Q4 Loss, Misses Revenue Estimates

Key Facts

1Marker Therapeutics reported a quarterly loss of $0.04 per share.
2The results significantly beat the Zacks Consensus Estimate of a $0.21 loss per share.
3The company exceeded revenue estimates for the fourth quarter.

FiscalNote Holdings (NOTE) reported a fourth-quarter loss of $0.66 per share, slightly outperforming the Zacks Consensus Estimate of a $0.67 loss. This result represents a significant year-over-year improvement compared to the $1.2 per share loss recorded in the same period last year. Despite the narrower-than-expected loss, the company's revenue for the quarter fell short of analyst projections. The financial results highlight the company's progress in reducing its net losses while facing challenges in top-line growth. Investors are evaluating the mixed performance as the company navigates its path toward profitability. The stock's reaction reflects the balance between the earnings beat and the revenue miss in the current market environment.